Landmarks in non-muscle-invasive bladder cancer

Mertens, Laura S.; Neuzillet, Y.; Horenblas, Simon; Rhijn, Bas W.G. van

doi:10.1038/nrurol.2014.130

Cited by 24 publications

(17 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BC is a molecularly heterogeneous disease, 36 and we find that the circRNA expression is also highly variable within prognostic subclasses. Generally, when we look at the expression of individual circRNAs, we observe many samples with zero reads and a subset with high circRNA expression (Fig.…”

Section: Resultsmentioning

confidence: 79%

Circular RNA expression is abundant and correlated to aggressiveness in early-stage bladder cancer

et al. 2017

View full text Add to dashboard Cite

The functions and biomarker potential of circular RNAs (circRNAs) in various cancer types are a rising field of study, as emerging evidence relates circRNAs to tumorigenesis. Here, we profiled the expression of circRNAs in 457 tumors from patients with non-muscle-invasive bladder cancer (NMIBC). We show that a set of highly expressed circRNAs have conserved core splice sites, are associated with Alu repeats, and enriched with Synonymous Constraint Elements as well as microRNA target sites. We identified 113 abundant circRNAs that are differentially expressed between high and low-risk tumor subtypes. Analysis of progression-free survival revealed 13 circRNAs, among them circHIPK3 and circCDYL, where expression correlated with progression independently of the linear transcript and the host gene. In summary, our results demonstrate that abundant circRNAs possess multiple biological features, distinguishing them from low-expressed circRNAs and non-circularized exons, and suggest that circRNAs might serve as a new class of prognostic biomarkers in NMIBC.

show abstract

Section: Resultsmentioning

confidence: 79%

Circular RNA expression is abundant and correlated to aggressiveness in early-stage bladder cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Urothelial bladder cancer (UBC) is the fifth most common cancer worldwide [ 1 ] and is one of the most management intensive cancers in North America [ 2 ]. Although the majority of incident cases of UBC are non-invasive at presentation, muscle invasive bladder cancer (MIBC) represents very aggressive disease with rapid progression to metastases [ 3 ] and poor overall survival despite intensive local and systemic therapy.…”

Section: Introductionmentioning

confidence: 99%

Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance

et al. 2017

View full text Add to dashboard Cite

Recent efforts on genome wide profiling of muscle invasive bladder cancer (MIBC) have led to its classification into distinct genomic and transcriptomic molecular subtypes that exhibit variability in prognosis. Evolving evidence from recent immunotherapy trials has demonstrated the significance of pre-existing tumour immune profiles that could guide treatment decisions. To identify immune gene expression patterns associated with the molecular subtypes, we performed a comprehensive in silico immune transcriptomic profiling, utilizing transcriptomic data from 347 MIBC cases from The Cancer Genome Atlas (TCGA). To investigate subtype-associated immune gene expression patterns, we assembled 924 immune response genes and specifically those involved in T-cell cytotoxicity and the Type I/II interferon pathways. A set of 157 ranked genes was able to distinguish the four subtypes in an unsupervised analysis in an original training cohort (n=122) and an expanded, validation cohort (n=225). The most common overrepresented pathways distinguishing the four molecular subtypes, included JAK/STAT signaling, Toll-like receptor signaling, interleukin signaling, and T-cell activation. Some of the most enriched biological processes were responses to IFN-γ, antigen processing and presentation, cytokine mediated signaling, hemopoeisis, cell proliferation and cellular defense response in the TCGA cluster IV. Our novel findings provide further insights into the association between genomic subtypes and immune activation in MIBC and may open novel opportunities for their exploitation towards precise treatment with immunotherapy.

show abstract

“…Approximately 75% of patients with bladder cancer present with non‐muscle invasive bladder cancer (NMIBC) defined as stage Ta, T1 or carcinoma in situ (CIS) . The prognosis for NMIBC is generally good, with disease‐specific survival in Ta stages of >96% over 5 years ; however, of significant concern in the treatment of NMIBC are the generally high rates of recurrence, estimated to be between 50 and 70% within 5 years of initial diagnosis .…”

Section: Introductionmentioning

confidence: 99%

Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue‐light cytoscopy in transurethral bladder tumour resection for patients with non‐muscle‐invasive bladder cancer in Sweden

et al. 2015

View full text Add to dashboard Cite

ObjectivesTo explore the cost impact on Swedish healthcare of incorporating one instillation of hexaminolevulinate hydrochloride (HAL) blue-light cystoscopy into transurethral resection of bladder tumour (TURBT) in patients with suspected new or recurrent non-muscle-invasive bladder cancer (NMIBC). Materials and MethodsA decision tree model was built based on European Association of Urology guidelines for the treatment and management of NMIBC. Input data were compiled from two recent studies comparing recurrence rates of bladder cancer in patients undergoing TURBT with either the current standard of care (SOC) of white-light cystoscopy, or with the SOC and HAL blue-light cystoscopy. Using these published data with clinical cost data for surgical and outpatient procedures and pharmaceutical costs, the model reported on the clinical and economic differences associated with the two treatment options. ResultsThis model demonstrates the significant clinical benefits likely to be observed through the incorporation of HAL blue-light cystoscopy for TURBT in terms of reductions in recurrences of bladder cancer. Analysis of economic outputs of the model found that the use of one instillation of HAL for TURBT in all Swedish patients with NMIBC is likely to be cost-neutral or cost-saving over 5 years relative to the current SOC of white-light cystoscopy. ConclusionsThe results of this analysis provide additional health economic rationale for the incorporation of a single instillation of HAL blue-light cystoscopy for TURBT in the treatment of patients with NMIBC in Sweden.

show abstract

Landmarks in non-muscle-invasive bladder cancer

Cited by 24 publications

References 57 publications

Circular RNA expression is abundant and correlated to aggressiveness in early-stage bladder cancer

Circular RNA expression is abundant and correlated to aggressiveness in early-stage bladder cancer

Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance

Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue‐light cytoscopy in transurethral bladder tumour resection for patients with non‐muscle‐invasive bladder cancer in Sweden

Contact Info

Product

Resources

About